Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
FRUTA FRUTA, First Half Ordinary Profit Increases by 3.7 times, Jul-Sep Ordinary Profit Increases by 40%
2586 FRUTA FRUTA INC. 【J-GAAP】
Earnings ReportFRUTA FRUTA INC. <2586> [TSE Growth] announced its financial results after the market closed on November 13th (15:30). The ordinary profit (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2026 (April to September) surged 3.7 times that of the same period last year, reaching 242 million yen. Progress toward the full-year plan of 370 million yen was 65.4%, also surpassing progress of 28.2% from the same period of the previous year.
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary profit for the October to March period (second half) is expected to decrease 23.8% from the same period last year to 128 million yen.
In the most recent three-month period, from July to September (2Q), the ordinary profit increased 39.7% from the same period last year, reaching 88 million yen. The operating profit margin improved from 8.1% in the same period last year to 9.4%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2023 | 576 | -144 | -157 | -157 | -4.9 | ー | Nov 13, 2023 | J-GAAP |
| Apr - Sep, 2024 | 1,125 | 67 | 66 | 54 | 1.2 | 28.2 | Nov 13, 2024 | J-GAAP |
| Apr - Sep, 2025 | 2,058 | 254 | 242 | 204 | 2.5 | 65.4 | Nov 13, 2025 | J-GAAP |
| YoY | +82.9% | +279.1% | +266.7% | +277.8% | +106.6% |
First Half Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2025 Guidance | ー | ー | ー | ー | - | 0 | May 15, 2025 | J-GAAP |
| Apr - Sep, 2025 Results | 2,058 | 254 | 242 | 204 | 2.5 | 0 | Nov 13, 2025 | J-GAAP |
| Revision Rate | - | - | - | - | - |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 1,424 | 162 | 168 | 216 | 3.8 | 0 | May 15, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 1,942 | 146 | 128 | 96 | 1.0 | 0 | Nov 13, 2025 | J-GAAP |
| YoY | +36.4% | -9.9% | -23.8% | -55.6% | -73.9% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 1,136 | -263 | -306 | -306 | -9.0 | 0 | May 15, 2024 | J-GAAP |
| Mar, 2025 | 2,549 | 229 | 234 | 270 | 4.7 | 0 | May 15, 2025 | J-GAAP |
| Mar, 2026 Guidance | 4,000 | 400 | 370 | 300 | 3.1 | 0 | May 15, 2025 | J-GAAP |
| YoY | +56.9% | +74.7% | +58.1% | +11.1% | -34.9% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Sep, 2024 | 653 | 53 | 63 | 51 | 1.2 | 8.1 | Nov 13, 2024 | J-GAAP |
| Oct - Dec, 2024 | 636 | 75 | 79 | 64 | 1.3 | 11.8 | Feb 12, 2025 | J-GAAP |
| Jan - Mar, 2025 | 788 | 87 | 89 | 152 | 2.7 | 11.0 | May 15, 2025 | J-GAAP |
| Apr - Jun, 2025 | 1,068 | 161 | 154 | 132 | 1.7 | 15.1 | Aug 14, 2025 | J-GAAP |
| Jul - Sep, 2025 | 990 | 93 | 88 | 72 | 0.9 | 9.4 | Nov 13, 2025 | J-GAAP |
| YoY | +51.6% | +75.5% | +39.7% | +41.2% | -22.6% |
Related Articles
Japan Animal Referral Medical, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 20%, Raises Record High Profit Forecast
Noile-Immune Biotech, The Current Fiscal Year's Undisclosed Net Income to Narrow
SPRIX, 13% Increase in Ordinary Profit for The Current Fiscal Year
ITFOR, First Half Ordinary Profit Revised Downward to an Unexpected 21%Decrease, Current Fiscal Year Dividend Revised Upward by 20 Yen
Jibannet, First Half Net Income Turns to Loss, Jul-Sep Net Income Decreases by 40%
jig.jp, First Half Ordinary Profit Decreases by 3%, Jul-Sep Ordinary Profit Decreases by 11%
JAPAN INSULATION, First Half Ordinary Profit Increases by 73%, Jul-Sep Ordinary Profit Increases by 65%
BRUNO, Jul-Sep (1Q) Ordinary Profit Turns to Profit
CHANGE Holdings, First Half Net Income Decreases by 25%
Rebase, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 86%